Skip to main content
SpringerLink
Log in

Guidelines for the Treatment of Preoperative Anaemia with Epoetin

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Recombinant human erythropoietin (epoetin) has been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union and Canada since 1993, 1994 and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1996. Early clinical trials of epoetin therapy in the setting of ABD have provided important information with respect to clinical safety, dose and erythropoietic response. Later trials of perisurgical epoetin therapy without ABD provided data on efficacy (i.e. reduced allogeneic blood exposure) that led to approval of epoetin in this setting.

However, the epoetin doses (300 U/kg subcutaneously × 14 days) used in these trials, and their subsequent inclusion in labelling for the use of this product, are costly to administer. A recent study has indicated that weekly administration of epoetin 600 U/kg over 4 weeks is just as effective but less costly than a daily regimen over 2 weeks. The most cost-effective regimen that has been shown to minimise allogeneic exposure is preoperative epoetin therapy with 600 U/kg/ week × 2 plus 300 U/kg on the day of surgery, coupled with acute normovolaemic haemodilution in patients undergoing radical retropubic prostatectomy. A similar regimen of epoetin therapy in patients undergoing coronary artery bypass grafting (2500 U/kg in divided doses over 2 weeks preoperatively) coupled with ‘blood pooling’, has also been described. ‘Low dose’ epoetin therapy coupled with acute normovolaemic haemodilution is cost-equivalent to the predonation of 3 autologous blood units, and may replace this strategy as a standard of care in the elective surgical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933–8

    Article  PubMed  CAS  Google Scholar 

  2. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28–35

    PubMed  CAS  Google Scholar 

  3. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988; 260: 65–7

    Article  PubMed  CAS  Google Scholar 

  4. Goodnough LT, Rudick S, Price TH, et al. Increased collection of autologous blood preoperatively with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163–7

    Article  PubMed  CAS  Google Scholar 

  5. Goodnough LT, Price TH, Rudnick S. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441–5

    Article  PubMed  CAS  Google Scholar 

  6. Goodnough LT, Price TH, EPO Study Group. A phase III trial of recombinant human erythropoietin therapy in non-anemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66–71

    Article  PubMed  CAS  Google Scholar 

  7. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. Vox Sang 1993; 65: 212–8

    Article  PubMed  CAS  Google Scholar 

  8. Biesma DH, Marx JJ, Kraaijenhagen RJ, et al. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994; 344: 367–70

    Article  PubMed  CAS  Google Scholar 

  9. Goodnough LT, Monk TG, Brecher MF. Autologous blood procurement: lessons to be learned in the last 10 years. Vox Sang 1996; 71: 133–41

    Article  PubMed  CAS  Google Scholar 

  10. Mercuriali F, Zanella A, Barosi G, et al. Use erythropoietin to increase the volume of autologous blood donated by orthopaedic patients. Transfusion 1993; 33: 55–60

    Article  PubMed  CAS  Google Scholar 

  11. Price TH, Goodnough LT, Vogler W, et al. The effect of recombinant erythropoietin administration on the efficacy of autologous blood donation in patients with low hematocrits. Transfusion 1996; 36: 29–36

    Article  PubMed  CAS  Google Scholar 

  12. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993; 341: 1227–32

    Google Scholar 

  13. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients undergoing major orthopaedic surgery. J Bone Joint Surg 1996; 78A: 62–72

    Google Scholar 

  14. de Andrade JR, Jove M, Landon G, et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alpha in orthopedic surgery patients. Am J Orthop 1996: 25: 533–42

    PubMed  Google Scholar 

  15. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718–22

    PubMed  CAS  Google Scholar 

  16. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990; 29: 709–13

    Article  PubMed  CAS  Google Scholar 

  17. Besarab A, Flaharty KK, Ervslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 9: 1405–16

    Google Scholar 

  18. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–8

    Article  PubMed  CAS  Google Scholar 

  19. Muirhead N. Recombinant human erythropoietin (epoietin alpha) in anemic patients on hemodialysis: Canada. In: Erslev AJ, editor. Erythropoietin. Baltimore (MD): Johns Hopkins University Press, 1991: 241–68

    Google Scholar 

  20. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993; 10: 1672–5

    Google Scholar 

  21. Taylor JE, Henderson IS, Stewart WK, et al. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338: 1361–2

    Article  PubMed  CAS  Google Scholar 

  22. Taylor JE, Belch JJF, McLaren M, et al. Effect of erythropoietin therapy and blood withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44: 182–90

    Article  PubMed  CAS  Google Scholar 

  23. Gordge MP, Leaker B, Patel A, et al. Recombinant human erythropoietin shortens the uremic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171–82

    Article  PubMed  CAS  Google Scholar 

  24. Vigano G, Benigni A, Mendogni P, et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 1: 44–9

    Google Scholar 

  25. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications for erythropoietin therapy. Lancet 1988; I: 97–100

    Article  Google Scholar 

  26. Goodnough LT, Monk TG. Evolving concepts in autologous blood procurement: case reports of perisurgical anemia complicated by myocardial infarction. Am J Med 1996; 101: 12a–33s

    Article  Google Scholar 

  27. Biesma DH, Bronkhorst PJH, de Groot PG, et al. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med 1994; 124: 42–7

    PubMed  CAS  Google Scholar 

  28. Sowade O, Ziemer S, Sowade B, et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostatis in patients undergoing cardiac surgery. J Lab Clin Med 1997; 129: 376–83

    Article  PubMed  CAS  Google Scholar 

  29. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood 1997; 89: 411–8

    PubMed  CAS  Google Scholar 

  30. Sowade O, Gross J, Sowade B, et al. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. J Lab Clin Med 1997; 129: 97–105

    Article  PubMed  CAS  Google Scholar 

  31. D’Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686–93

    Article  PubMed  Google Scholar 

  32. Goodnough LT, Despostis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997; 64: 1579–80

    Article  PubMed  CAS  Google Scholar 

  33. Gaudiani VA, Mason HDW. Preoperative erythropoietin in Jehovah’s Witnesses who require cardiac procedures. Ann Thorac Surg 1991; 51: 823–4

    Article  PubMed  CAS  Google Scholar 

  34. Monk TG, Goodnough LT, Andreole GL, et al. Preoperative recombinant human erythropoietin enhances the efficacy of acute normovolemic hemodilution. Anesth Analg 1995; 80: S320

    Google Scholar 

  35. Hogue CW, Goodnough LT, Ding Y, Monk TG. Myocardial ischemic episodes in elderly patients having autologous blood procurement. Anesthesiology 1996; 85: A50

    Article  Google Scholar 

  36. Goodnough LT, Verbrugge D, Marcus RE, et al. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg 1994; 179; 171–6

    PubMed  CAS  Google Scholar 

  37. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57–64

    PubMed  CAS  Google Scholar 

  38. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang. In press

  39. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol 1994; 87: 695–9

    Article  PubMed  CAS  Google Scholar 

  40. Coleman PH, Stevens AR, Dodge HT, et al. Rate of blood regeneration after blood loss. Arch Int Med 1953; 92: 341–8

    Article  CAS  Google Scholar 

  41. Crosby WH. Treatment of hemochromatosis by energetic phlebotomy: one patient’s response to getting 55 liters of blood in 11 months. Br J Haematol 1958; 4: 82–8

    Article  PubMed  CAS  Google Scholar 

  42. Goodnough LT, Merkel K. The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Int J Hematol 1996; 1: 163–6

    CAS  Google Scholar 

  43. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60: 1241–6

    PubMed  CAS  Google Scholar 

  44. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992; 120: 746–51

    PubMed  CAS  Google Scholar 

  45. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopaedic patients. Transfusion 1993; 33: 55–9

    Article  PubMed  CAS  Google Scholar 

  46. Toy PTCY, Kaplan EB, McVay PA, et al. Blood loss and replacement in total hip arthroplasty: a multicenter study. Transfusion 1992; 32: 63–7

    Article  PubMed  CAS  Google Scholar 

  47. Goodnough LT, Vizmeg K, Marcus RE. Blood lost and transfused in patients undergoing elective orthopaedic operation: implications for blood conservation programs. Surg Gynecol Obstet 1993; 176: 235–8

    PubMed  CAS  Google Scholar 

  48. Sisk JE, Gianfrancesco FD, Costner JM. Recombinant erythropoetin and medicare payment. JAMA 1991; 266: 247–52

    Article  PubMed  CAS  Google Scholar 

  49. Doolittle RF. Biotechnology —the enormous cost of success. N Engl J Med 1991; 324: 1360–62

    Article  PubMed  CAS  Google Scholar 

  50. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of erythropoietin alpha in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 544–52

    PubMed  CAS  Google Scholar 

  51. Sans T, Bofill C, Joven J, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 1996; 36: 822–6

    Article  PubMed  CAS  Google Scholar 

  52. Messmer K, Kreimeier M, Intagliett A. Present state of intentional hemodilution. Eur Surg Res 1986; 18: 254–63

    Article  PubMed  CAS  Google Scholar 

  53. Monk TG, Goodnough LT, Birkmeyer JD, et al. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous donation in patients undergoing radical retropubic prostatectomy. Transfusion 1995; 35: 559–65

    Article  PubMed  CAS  Google Scholar 

  54. Monk TG, Goodnough LT, Pulley DD, et al. Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in patients undergoing radical prostatectomy procedures. Anesth Analg 1997; 85: 953–8

    PubMed  CAS  Google Scholar 

  55. Andriole GL, Smith DS, Rao G, et al. Early complications of contemporary anatomic radical retropubic prostatectomy. J Urol 1994; 152: 1858–60

    PubMed  CAS  Google Scholar 

  56. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. Am J Med Qual 1994; 9: 172–83

    Article  PubMed  CAS  Google Scholar 

  57. Welch GH, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 393–402

    PubMed  CAS  Google Scholar 

  58. Goodnough LT. Blood transfusion and blood conservation practices: flip sides of the same coin? Ann Thorac Surg 1993; 56: 13–4

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Laboratory Medicine, Washington University School of Medicine, Box 8118, 660 S. Euclid Avenue, St Louis, MO, 63110, USA

    Lawrence T. Goodnough

Authors
  1. Lawrence T. Goodnough
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence T. Goodnough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goodnough, L.T. Guidelines for the Treatment of Preoperative Anaemia with Epoetin. BioDrugs 10, 183–191 (1998). https://doi.org/10.2165/00063030-199810030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199810030-00002

Keywords

Search

Navigation